Skip to content
  1. Home
  2. Fitness & muscle
  3. Sermorelin

Fitness & muscle

Sermorelin

The original, FDA-approved GHRH analog (its approved brand was later discontinued), the natural-sequence precursor that CJC-1295/Mod-GRF are modified versions of.

Formerly FDA-approved Fitness & muscle

Reviewed 2026-09-12
Full name
Sermorelin (GHRH 1-29, the natural-sequence growth hormone releasing hormone fragment)
Also known as
GRF 1-29, Geref (discontinued brand)
Regulatory status
Was FDA-approved (as Geref) for diagnostic testing of growth hormone deficiency and as a treatment for GH deficiency in children; the branded product was discontinued for commercial reasons, not safety. Now mainly available through compounding pharmacies (often prescribed off-label by anti-aging/hormone clinics) or research-chemical vendors.

Origin

The first 29 amino acids of the naturally occurring 44-amino-acid GHRH molecule, the shortest fragment found to retain full GH-releasing activity.

Mechanism

Same mechanism as the modified GHRH analogs: binds GHRH receptors in the pituitary, stimulating release of stored growth hormone in a pulsatile, physiological pattern. Preserves the body's natural negative-feedback regulation, unlike direct HGH injection.

Research summary

Evidence

Because it held actual FDA approval, sermorelin has more legitimate human clinical trial history behind it than most GH secretagogues discussed in self-experimentation circles, including diagnostic pharmacokinetic data and pediatric GH-deficiency treatment trials. Its short half-life, a few minutes, versus modified analogs like CJC-1295 with DAC, is generally seen as an advantage for preserving physiological pulsatility, not a downside.

Evidence tier: Formerly FDA-approved — see the methodology note for how this is assessed.

Citations

Reported benefits

  • Improved sleep quality
  • Used in anti-aging/hormone-optimization clinics specifically for adults with low-normal IGF-1 as a 'gentler' alternative to direct HGH therapy
  • Considered by some clinicians a reasonable starting point for GH-axis support given its approval history, even though current off-label use for aging/body composition isn't itself trial-validated

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Subcutaneous injection, nightlyA commonly used clinical/off-label dose is 200-300 mcg injected subcutaneously at bedtime, daily, aiming to align with the largest natural nighttime GH pulse.

Side effects

  • Injection-site reactions
  • Flushing, headache reported in some users, generally at higher doses
  • Same general GH-axis caveats as other secretagogues: fluid retention, joint discomfort possible with sustained elevated GH/IGF-1

Safety notes

Safety: Among the more reassuring GH secretagogues given its genuine (if now discontinued as a branded product) FDA approval history. Current off-label adult use for body composition/anti-aging isn't the indication that approval was based on.
Community & reddit notes (anecdotal — not clinical evidence)

Often recommended by hormone-optimization clinics as a first step before GHRP combinations. Some in self-experimentation communities view it as 'safer by reputation' than compounds that never went through any approval process, even though day-to-day self-administered use isn't itself clinically validated.